Correction to: The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice

Correction to: Alzheimers Res Ther 13, 6 (2021)

https://0-doi-org.brum.beds.ac.uk/10.1186/s13195-020-00743-x

Following publication of the original article [1], the authors reported an error in Figure 5 and Supplementary Figure 9. In Figure 5, the same image was included, by mistake, in panels c and d. The corrected Figure 5 shows the correct image in panel c. Similarly, in Supplementary Figure 9, panels G and K show, by mistake, the same image. The corrected Supplementary Figure 9 shows the correct image in panel G, presented below as Fig. 1.

Fig. 1

Analysis of pre-synapse and post-synapse in the CA3 region. Brain sections were stained using anti-bassoon (a–e) or anti-homer (g–k) antibodies. Representative images are shown for a, g) wild-type mice treated with vehicle (WT-0), b, h) wild-type mice treated with 1.0 mg/Kg CLR01 (WT-1.0), c, i) P301S-tau mice treated with vehicle (Tg-0), d, j) P301S-tau mice treated with 0.3 mg/Kg CLR01 (Tg-0.3), and e, k) P301S-tau mice treated with 1.0 mg/Kg CLR01. The data were quantified as the number of puncta per unit area in the CA3 region for Bassoon (f) and Homer (l)

Fig. 5

CLR01 treatment reduces hyperphosphorylated tau in the hippocampus of P301S-tau mice. Brain sections from P301S-tau mice were stained with monoclonal antibody AT8 and visualized by immunofluorescence. a The typical crescent shape of the hippocampus was delineated by an operator blinded to treatment. b–d Representative images of the hippocampus area of mice treated with 0 (a), 0.3 (b), or 1.0 (c) mg/kg per day CLR01. d The data were quantified as the percentage of AT8-positive area within the hippocampus area, as defined in panel a. The data are presented as mean ± SD. P values were calculated using a one-way ANOVA with post hoc Tukey test